Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001665124-26-000013
Filing Date
2026-07-10
Accepted
2026-07-10 18:54:36
Documents
1
Period of Report
2026-07-10

Document Format Files

Seq Description Document Type Size
1 form4-07102026_100732.html 4  
1 form4-07102026_100732.xml 4 4018
  Complete submission text file 0001665124-26-000013.txt   5502
Mailing Address C/O AVEXIS, INC., 2275 HALF DAY ROAD SUITE 160 BANNOCKBURN IL 60015
Business Address
Nagendran Sukumar (Reporting) CIK: 0001665124 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39536 | Film No.: 261169736

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Issuer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)